| Followers | 30 |
| Posts | 3322 |
| Boards Moderated | 0 |
| Alias Born | 08/21/2015 |
Saturday, January 02, 2021 3:06:06 PM
“I think NP has already stated they would release unblinded data on the 14th.”
I don’t recall NP mentioning that exact date, but the full enrollment PR stated, “The 390-patient data will be analyzed in approximately 28 days, with expected results to be announced shortly thereafter.”
https://www.cytodyn.com/newsroom/press-releases/detail/491/cytodyn-completes-enrollment-for-phase-3-registrational
Completion of the 28th day is the 12th of January and the 14th is a few days later, but that seems rushed to publish such important results. NP typically over promises, but a decent amount, so I expect the data to be released a week or two after the 12th. CYDY needs to take their time to fully analyze the data and publish a through and well thought out PR discussing the results. We don’t need a repeat of the two different M2M PRs, spread 3 weeks apart, of which one had to be released a second time a few hours later. That was a debacle.
I don’t recall NP mentioning that exact date, but the full enrollment PR stated, “The 390-patient data will be analyzed in approximately 28 days, with expected results to be announced shortly thereafter.”
https://www.cytodyn.com/newsroom/press-releases/detail/491/cytodyn-completes-enrollment-for-phase-3-registrational
Completion of the 28th day is the 12th of January and the 14th is a few days later, but that seems rushed to publish such important results. NP typically over promises, but a decent amount, so I expect the data to be released a week or two after the 12th. CYDY needs to take their time to fully analyze the data and publish a through and well thought out PR discussing the results. We don’t need a repeat of the two different M2M PRs, spread 3 weeks apart, of which one had to be released a second time a few hours later. That was a debacle.
Recent CYDY News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/21/2026 04:15:12 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/20/2026 09:08:39 PM
- CytoDyn to Present at the LD Micro Invitational XVI • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
